Today: 19 April 2026
Vodafone share price edges up as buyback rolls on and broker lifts valuation
11 February 2026
1 min read

Vodafone share price edges up as buyback rolls on and broker lifts valuation

London, Feb 11, 2026, 09:21 GMT — Regular session.

Vodafone (VOD.L) edged up 0.7% to 112.30 pence just after the open in London on Wednesday, with the telecoms giant continuing its share buyback program, according to shareprices.com at 0909 GMT.

The buyback has taken on added significance as Vodafone continues to rely on cash returns amid efforts to steady its core European business. Chief Executive Margherita Della Valle said the group remains “on track to deliver at the upper end of our guidance range for both profit and cash flow.” Vodafone, for its part, noted it has wrapped up €3.5 billion in buybacks so far, and is pressing ahead with a fresh €500 million tranche. Vodafone

On Wednesday morning, broker desks kept an eye on the stock. DZ Bank bumped up its fair value estimate for Vodafone, moving it to 130 pence from the previous 120 pence, while sticking with a “buy” rating, according to Alliance News. Share Prices

Vodafone picked up 22.3 million shares on Feb. 10, paying an average of 113.18 pence each, with prices ranging from 112.30 to 114.75 pence. The shares, acquired from Goldman Sachs International, are headed for treasury, according to the company.

Vodafone snapped up 23.4 million shares at an average 112.70 pence apiece the previous day, according to its latest filing. That brings the tally to around 45.7 million shares across just two sessions, the company’s numbers show.

Vodafone’s buyback began in the wake of its third-quarter numbers last week, which showed group organic service revenue up 5.4%. Adjusted EBITDAaL, the company’s metric for core earnings post-leases, climbed 2.3%. Full-year guidance stayed put: adjusted EBITDAaL between €11.3 billion and €11.6 billion, and adjusted free cash flow still expected in the €2.4 billion to €2.6 billion range.

Yet the shares still carry the weight of a recovery bet, leaving space for letdowns. Last week, Vodafone’s CEO flagged Germany—crucial for the group—as “still competitive,” and investors are eyeing whether momentum sticks into the next quarter. Reuters

Vodafone heads into its FY26 results on May 12, with investors looking for details on cash flow, guidance, and how quickly capital returns are coming along.

Stock Market Today

  • How Defensive Stocks Could Boost Your 401(k) This Summer
    April 18, 2026, 10:58 PM EDT. Seasonal stock market trends suggest selling in May, but experts caution against it in 2026. Instead, financial analysts Mark Hulbert and Sam Stovall recommend rotating investments into defensive stocks during the summer months. These stocks, found in sectors like healthcare and consumer staples, are less sensitive to economic swings and provide stable returns. Hulbert advises using ETFs such as Consumer Staples Select Sector SPDR (XLP) and Health Care Select Sector SPDR (XLV) for this strategy. These ETFs offer low fees and exposure to essential goods and services companies, offering potential portfolio stability during typical market volatility in May to October. This approach could make a meaningful difference to your 401(k) performance by balancing growth and risk through seasonal shifts.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
London Stock Exchange Group (LSEG) share price jumps on Elliott stake report as buyback debate flares up
Previous Story

London Stock Exchange Group (LSEG) share price jumps on Elliott stake report as buyback debate flares up

Quince Therapeutics (QNCX) stock price jumps in premarket as strategic review keeps deal talk alive
Next Story

Quince Therapeutics (QNCX) stock price jumps in premarket as strategic review keeps deal talk alive

Go toTop